Meeting
2020 ASCO Virtual Scientific Program
Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.
Authors
Abed Rahman Kawakibi
Michigan Medicine, Ann Arbor, MI
Abed Rahman Kawakibi , Rohinton Tarapore , Sharon L. Gardner , Sylvia Christine Kurz , Patrick Y. Wen , Isabel Arrillaga-Romany , Tracy Batchelor , Nicholas A. Butowski , Ashley Love Sumrall , Nicole A. Shonka , Rebecca A. Harrison , John Frederick De Groot , Minesh P. Mehta , Yazmin Odia , Matthew David Hall , Timothy Francis Cloughesy , Benjamin M. Ellingson , Yoshie Umemura , Joshua E. Allen , Carl Johannes Koschmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03295396, NCT03416530, NCT02525692
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3617)
DOI
10.1200/JCO.2020.38.15_suppl.3617
Abstract #
3617
Poster Bd #
347
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.
First Author: Sharon L. Gardner
Poster
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
First Author: Sylvia Christine Kurz
Poster
2020 ASCO Virtual Scientific Program
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
First Author: Isabel Arrillaga-Romany
First Author: Sharon L. Gardner